Analysis of immunoexpression of common cancer stem cell markers in ameloblastoma
Sathi, G.A.; Tamamura, R.; Tsujigiwa, H.; Katase, N.; Lefeuvre, M.; Siar, C.H.; Matsuda, H.; Nagatsuka, H. (2012) Analysis of immunoexpression of common cancer stem cell markers in ameloblastoma. Experimental and Therapeutic Medicine, 3 (3). pp. 397-402. ISSN 1792-0981
Recent studies have established that, in benign tumors, a large number of cancer stem cells are present, which have great implications in tumor development. However, in ameloblastoma, a highly aggressive, locally invasive tumor with a high recurrence rate, whether or not cancer stem-like cells are present remains undetermined. Therefore, in this study we analyzed the protein expression of three candidate stem cell markers in ameloblastoma. Immunohistochemical staining for cancer stem cell (CSC) markers (CD133, CD44 and ABCG2) and for the proliferation marker Ki-67 was performed using 23 ameloblastoma cases. In all 23 samples, CD 133, CD44 and ABCG2 were expressed. Nine (39.13) cases showed high expression and 14 cases (60.87) showed low expression for CD133. Twelve of the 23 cases (52.17) showed high expression and 11 cases (47.83) showed low expression for both CD44 and ABCG2, respectively. Ki-67 was mainly expressed in peripheral ameloblast-like cells, suggesting that these cells have a higher degree of differentiation and, therefore, are less likely to contain cancer stem-like cells. On the other hand, cells positive for CSC markers situated at the close proximity to peripheral cells were devoid of Ki-67 and may have the potential to be cancer stem-like cells. After analyzing the correlation between expression of three CSC markers with clinicopathological factors and Ki-67 expression, only CD44 expression was correlated with tumor recurrence (P=0.0391). In conclusion, this study showed various expression patterns of different types of cancer stem cell markers and the presence of candidate CSC-like cells in ameloblastoma, which are possibly involved in cell proliferation, tumor progression and recurrence.
|Item Type: ||Article|
- Sathi, G.A.
- Tamamura, R.
- Tsujigiwa, H.
- Katase, N.
- Lefeuvre, M.
- Siar, C.H.
- Matsuda, H.
- Nagatsuka, H.
|Journal or Publication Title: ||Experimental and Therapeutic Medicine|
|Additional Information: ||ISI Document Delivery No.: 893FF Times Cited: 0 Cited Reference Count: 31 Cited References: Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100 Bleau AM, 2009, CELL CYCLE, V15, P2936 Burkert J, 2006, J PATHOL, V209, P287, DOI 10.1002/path.2016 Chen Z, 2010, INT J CANCER, V126, P841, DOI 10.1002/ijc.24796 Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126 Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018 Felthaus O, 2011, BIOCHEM BIOPH RES CO, V407, P28, DOI 10.1016/j.bbrc.2011.02.084 Gardner DG, 2005, WHO CLASSIFICATION T, P296 Huang X, 2011, SURG ONCOL 0714 Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962 Kim JE, 2009, MODERN PATHOL, V22, P1312, DOI 10.1038/modpathol.2009.98 Kumamoto H, 2010, J ORAL PATHOL MED, V39, P87, DOI 10.1111/j.1600-0714.2009.00807.x Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030 Liao XY, 2009, CARCINOGENESIS, V30, P131, DOI 10.1093/carcin/bgn230 Mitsuyasu T, 1997, J ORAL PATHOL MED, V26, P345, DOI 10.1111/j.1600-0714.1997.tb00228.x Neuzil J, 2007, BIOCHEM BIOPH RES CO, V355, P855, DOI 10.1016/j.bbrc.2007.01.159 Neville BW, 2009, ORAL MAXILLOFACIAL P, P702 O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372 Olempska M, 2007, HEPATOB PANCREAT DIS, V6, P92 Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104 Sathi GA, 2009, ORAL ONCOL, V45, P856, DOI 10.1016/j.oraloncology.2009.02.001 Sathi GSA, 2008, HISTOPATHOLOGY, V53, P458, DOI 10.1111/j.1365-2559.2008.03127.x Sathi GSA, 2008, J HARD TISSUE BIOL, V17, P63 Singh SK, 2003, CANCER RES, V63, P5821 Siriwardena BSMS, 2009, ORAL ONCOL, V45, P103, DOI 10.1016/j.oraloncology.2008.03.008 Steffensen K. D., 2011, J ONCOL Suetsugi A, 2006, BIOCHEM BIOPH RES CO, V351, P820, DOI 10.1016/j.bbrc.2006.10.128 Wu C, 2008, CANCER LETT, V268, P1, DOI 10.1016/j.canlet.2008.03.048 Xu, 2009, BRIT J CANCER, V101, P303 Zeki SS, 2011, NAT REV GASTRO HEPAT, V8, P90, DOI 10.1038/nrgastro.2010.211 Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028 Sathi, Gulsan Ara Tamamura, Ryo Tsujigiwa, Hidetsugu Katase, Naoki Lefeuvre, Mathieu Siar, Chong Huat Matsuda, Hiroyuki Nagatsuka, Hitoshi Japan Society for the Promotion of Science (JSPS)21592326; Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT)22791977, 20791337, 22791766 This study was supported by a Grant-in-Aid for Research (C) (no. 21592326) from the Japan Society for the Promotion of Science (JSPS), and a Grant-in-Aid for Young Scientists (B) (nos. 22791977, 20791337 and 22791766) from the Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT). Spandidos publ ltd Athens|
|Uncontrolled Keywords: ||Ameloblastoma cancer stem cell CD133 CD44 ABCG2 immunohistochemistry prospective identification carcinoma invasion|
|Subjects: ||R Medicine > RK Dentistry|
|Divisions: ||Faculty of Dentistry > Dept of Oral Pathology & Oral Medicine & Periodontology|
|Depositing User: ||Ms Nursyafiqah Abd Malek|
|Date Deposited: ||10 Jan 2013 08:17|
|Last Modified: ||10 Jan 2013 08:17|
Actions (login required)